Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULARGeneric

RYKINDO

RISPERIDONE

Standard Dose
12.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview RYKINDO is listed in Drugs@FDA under application 212849 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient RISPERIDONE Form and strength FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 12.5MG Sponsor SHANDONG LUYE Submission history Latest submission status date: 2026-01-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview RYKINDO is listed in Drugs@FDA under application 212849 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient RISPERIDONE Form and strength FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 12.5MG Sponsor SHANDONG LUYE Submission history Latest submission status date: 2026-01-16 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.